

DobesilTM

Calcium Dobesilate Capsule

Presentation

Dobesil™ Capsules: Each capsule contains Calcium Dobesilate Monohydrate BP equivalent to Calcium Dobesilate 500 mg

Description

Calcium Dobesilate is a vasoactive drug that presumes effects on endothelial integrity, capillary permeability and blood viscosity. It decreases capillary hyperpermeability, decreases platelet aggregation (clotting - adhesion of platelets) and reduces the serum viscosity, which improves blood circulation and blood supply to tissues and organs.

Indications and uses

DobesilTM is indicated for the treatment of hemorrhoidal syndrome, microcirculation disorders of arteovenous origin, clinical signs of chronic venous insufficiency in the lower limbs (pain, cramps, paresthesia, edema, stasis, dermotosis) and in the particular microangiopathy like diabetic retinopathy. It is also indicated in superficial thrombophlebitis as adjuvant therapy.

Dosage and administration

1 Dobesil™ capsule once or twice daily should be taken with the main meal. Treatment duration, which generally between a few weeks to several months, depends on the disease and its evolution. Dosage should be adapted individually according to the severity of the disease.

Contraindications

Known hypersensitivity to Calcium Dobesilate on any of the ingredients in the Dobesil™ capsule.

Side effects

Rarely gastrointestinal disorders including nausea and diarrhea, skin reactions, fever, articular pain and in very rare cases agranulocytosis have been reported. These reactions are generally spontaneously reversible after treatment withdrawal.

Precautions

- Dosage should be reduced in case of severe renal insufficiency requiring dialysis.
- In patient with agranulocytosis this medication can decrease the number of white blood cells which affect the body's ability to fight against various infections. If patients experience flu-like symptoms such as cough, sore throat, fever and others, they are advised to seek medical care as soon as possible.

Use in pregnancy and lactation

The safety of Calcium Dobesilate during pregnancy and lactation has not been established. As it is not known whether calcium dobesilate crosses the placental barrier in humans, the drug should be administered during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus. Avoid breastfeeding while using this medicine.

Overdose

The clinical signs of a possible overdose are not known. If overdose occurs, seek medical advice immediately.

Storage

Store in a cool and dry place, away from light. Keep out of the reach of children.

Commercial Pack

Dobesil™ Capsules: Each box contains 3 Alu-PVDC blister strips of 10 capsules.



Manufactured by

Pto Incepta Pharmaceuticals Ltd

Savar, Dhaka, Bangladesh

™ Trademark

2